Rocket Pharmaceuticals (RCKT) Stock Price, Quote, News & History | Benzinga

SPY774.72−0.32%QQQ752.96−0.63%BTC/USD81,260.67−2.42%DIA509.75−0.25%GLD376.70+0.22%TLT77.42+0.35%

Rocket Pharmaceuticals Inc (RCKT) Stock Price, Quote, News & History

RCKTNASDAQ

Trade with Public

Trade with Public

$2.59

0.0552.17%

Last update: Oct 8, 12:14 PM

$2.77

0.239.27%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$2.77

Close

-

Volume / Avg.

1.37M / 1.71M

Day Range

$2.52 - $2.77

52 Wk Range

2.42 - 5.45

Market Cap

$284.32M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

33

Short Interest

16.58%

Days to Cover

11.1

Recent Rocket Pharmaceuticals, Inc. News

This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Analysts upgraded Rocket Pharma, Generac, Palantir, Global Payments and Unity Software, with new or raised price targets.

Avi Kapoor

This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

Analysts upgraded SUNB, HAWK, and more, revising ratings and price targets.

Avi Kapoor

This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Analysts upgraded Similarweb, Rocket Pharmaceuticals, Radiant Logistics and Ulta Beauty; Paychex rose to Peer Perform, with targets raised.

Avi Kapoor

Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial

Rocket Pharmaceuticals announces positive early safety results for its RP-A501 Phase 2 trial in Danon disease and plans further FDA talks.

Vandana Singh

Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday

Top analysts changed ratings for OVV, ALMS, CLMT, LGN, RCKT, UTHR, VNT, HOOD. See full changes at benzinga.com/analyst-stock-ratings

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-170.27M

Investing Cash Flow (TTM)

361.85M

Financing Cash Flow (TTM)

82.00K

Free Cash Flow (TTM)

-170.39M

Capital Expenditure (TTM)

-127.00K

Net Change in Cash (TTM)

191.66M

Analyst Trends and Forecast

1

May

1

Aug

4

Sep

2

2

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.2

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$19.88M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

0.76

Earnings Yield % (TTM)

-6.69%

Earnings Yield % (FWD)

-5.12%

EV / EBITDA (TTM)

6.70

Price / EBITDA (TTM)

96.68

Price / Free Cash Flow (TTM)

-

Book Value / Share

$3.36

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$224.51M

Debt to Equity

0.07

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-